This clinical trial focuses on patients with recurrent genital herpes, a recurring viral infection that causes outbreaks of sores in the genital area. The study evaluates a new medication called IM-250, which is given as oral capsules once per week. The purpose is to determine if this new treatment can help control herpes outbreaks when used as a long-term preventive therapy.
The research involves testing different doses of IM-250 against a placebo to understand how well the medication works and how safe it is. The study is conducted in a double-blind manner, which means neither the patients nor the doctors know who receives which treatment during the study. Participants will take either the study medication or placebo weekly for several weeks.
During the trial, doctors will monitor how often participants experience viral shedding (when the virus becomes active and potentially contagious) and track the occurrence of herpes outbreaks. They will also study how the medication moves through the body and how long it remains active. The study includes regular check-ups and testing to ensure participant safety throughout the treatment period.
Bulgaria 
